Glaukos Corporation develops ophthalmic pharmaceuticals and medical devices focused on treating glaucoma, corneal disorders, and retinal diseases. The company's primary product portfolio includes the iStent and iStent inject W micro-bypass stents, which restore natural aqueous humor outflow pathways in patients with mild-to-moderate open-angle glaucoma. It also offers iStent infinite for treatment-resistant glaucoma and iDose TR, an intracameral pharmaceutical therapy for intraocular pressure reduction. The company is developing additional therapies including iLink for keratoconus treatment, ILution, a transdermal delivery platform for anterior segment disorders, and a retinal XR platform targeting posterior segment conditions such as age-related macular degeneration and diabetic macular edema.
Glaukos generates revenue primarily through direct sales to ambulatory surgery centers, hospitals, and physician practices in the United States and internationally. The company maintains a direct sales organization and subsidiaries supplemented by distributor partnerships to reach its customer base.
The company employs approximately 1,094 full-time employees and is headquartered in Aliso Viejo, California. Glaukos was incorporated in Delaware in 1998 and is listed on the NYSE.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-3.28 | $-3.28 | -18.4% | |
| 2024 | $-2.77 | $-2.77 | +0.4% | |
| 2023 | $-2.78 | $-2.78 | -321.2% | |
| 2022 | $-0.66 | $-0.66 | -40.4% | |
| 2021 | $-0.47 | $-0.47 | -95.8% | |
| 2020 | $-0.24 | $-0.24 | -128.6% | |
| 2019 | $0.84 | $0.92 | +2000.0% | |
| 2018 | $0.04 | $0.05 | +33.3% | |
| 2017 | $0.03 | $0.03 | — | |
| 2016 | $0.00 | $0.00 | +100.0% | |
| 2015 | $-0.07 | $-0.07 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-23 | 0001193125-26-061944 | SEC ↗ |
| 2024-12-31 | 2025-02-25 | 0001558370-25-001402 | SEC ↗ |
| 2023-12-31 | 2024-02-23 | 0001558370-24-001630 | SEC ↗ |
| 2022-12-31 | 2023-02-24 | 0001558370-23-002070 | SEC ↗ |
| 2021-12-31 | 2022-02-28 | 0001558370-22-002371 | SEC ↗ |
| 2020-12-31 | 2021-03-01 | 0001558370-21-002061 | SEC ↗ |
| 2019-12-31 | 2020-03-02 | 0001558370-20-001862 | SEC ↗ |
| 2018-12-31 | 2019-02-28 | 0001558370-19-001235 | SEC ↗ |
| 2017-12-31 | 2018-02-28 | 0001558370-18-001301 | SEC ↗ |
| 2016-12-31 | 2017-03-15 | 0001558370-17-001833 | SEC ↗ |
| 2015-12-31 | 2016-03-15 | 0001558370-16-004119 | SEC ↗ |